A Study of Subcutaneous KY1005 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions

Immune System Diseases

Interventions

DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

Trial Locations (1)

Hammersmith Medicines Research, London

All Listed Sponsors

lead

Kymab Limited

INDUSTRY

NCT04449939 - A Study of Subcutaneous KY1005 in Healthy Volunteers | Biotech Hunter | Biotech Hunter